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Abstract
Lupus nephritis (LN) is an autoimmune disorder in which co-stimulatory signals have been involved. Here we tested a
cholesterol-conjugated-anti-CD40-siRNA in dendritic cells (DC) in vitro and in a model of LPS to check its potency and tissue
distribution. Then, we report the effects of Chol-siRNA in an experimental model of mice with established lupus nephritis.
Our in vitro studies in DC show a 100%intracellular delivery of Chol-siRNA, with a significant reduction in CD40 after LPS
stimuli. In vivo in ICR mice, the CD40-mRNA suppressive effects of our Chol-siRNA on renal tissue were remarkably sustained
over a 5 days after a single preliminary dose of Chol-siRNA. The intra-peritoneal administration of Chol-siRNA to NZB/WF1
mice resulted in a reduction of anti-DNA antibody titers, and histopathological renal scores as compared to untreated
animals. The higher dose of Chol-siRNA prevented the progression of proteinuria as effectively as cyclophosphamide,
whereas the lower dose was as effective as CTLA4. Chol-siRNA markedly reduced insterstitialCD3+ and plasma cell infiltrates
as well as glomerular deposits of IgG and C3. Circulating soluble CD40 and activated splenic lymphocyte subsets were also
strikingly reduced by Chol-siRNA. Our data show the potency of our compound for the therapeutic use of anti-CD40-siRNA
in human LN and other autoimmune disorders.
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Introduction
Systemic lupus erythematosus (SLE) is a complex autoimmune
disorder affecting multiple organ systems including the kidney,
skin, lung, heart, hematopoietic system, and the brain. Type IV
glomerulonephritis leading to severe proteinuria, chronic renal
failure and end-stage renal disease (ESRD) remains one of the
most dreaded complications of SLE and is associated with
significant morbidity and mortality [1,2].
In lupus nephritis insufficient clearance of apoptotic nucleo-
somes has been postulated as the likely trigger of a T-cell response
leading to the formation of autoantibodies which then bind to the
glomerular basement membrane and promote inflammation [3,4].
Renal infiltration by B and T-cells, macrophages, and dendritic
cells is a prominent feature of progressive LN leading to renal
failure [1]. Some studies have highlighted the importance of T-
cells in stimulating the production of autoantibodies by B-cells in
SLE [5]. Such stimulatory role by T-cells requires the presence of
co-stimulatory signaling dyads, such as CD28/B7 or CD40/
CD154, without which B-cells may fail to proliferate or even
undergo apoptosis [6,7].
Among the therapeutic armamentarium available to treat LN,
cyclophosphamide (CYP) and steroids can effectively delay the
progression of renal disease [8,9], although failure to achieve
remission has been reported in 18–57% of patients. Furthermore,
the long term toxicity of CYP and high-dose steroids discourages
their chronic use to maintain disease remission [10].
NZB/W F1 mice spontaneously develop an autoimmune
disorder which resembles human SLE [11,12], including the
formation of auto-antibodies against multiple epitopes of
chromatin and nucleosomes and the presence of haemolytic
anemia, proteinuria, and overt nephritis [13,14], thus providing
a suitable experimental model in which to test potential new
therapeutic agents. For example, treatment with CTLA4 and a
suboptimal dose of CYP has been shown to significantly prolong
survival, although without evidence of reduced glomerular
immune-complex deposition. Therefore, blocking co-stimulatory
signals necessary for T cell activation appears to prevent disease
progression in these animals [1,15,16]. The co-stimulatory dyad
CD40/CD154 (CD40-ligand) has been previously implicated in
the pathogenesis of LN and other autoimmune disorders
[17,18].
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The administration of LPS is known to dramatically enhance
CD40 expression [19,20]. LPS, a Gram-negative cell wall
component recognized by the specific receptor TLR4, is an
adjuvant for the adaptive immune response, which up-regulates
costimulatory molecules on antigen presenting cells [19]. It has
been demonstrated that LPS induces CD40 mRNA and protein
expression in both murine and human kidney, heart, brain, small
intestine and circulating macrophages [19,20] thus providing a
uniquely challenging experimental model where to test the
potency and durability of effect of our specifically designed
CD40-siRNA.
RNA-interference (RNAi) is an evolutive innate cell mechanism
of post-transcriptional gene silencing, which has been successfully
replicated by the administration of synthetic double-stranded small
inhibitory RNA (siRNA). Rapid degradation by exo/endonucle-
ases constitutes a serious challenge to the successful intracellular
delivery of siRNAs in vivo and their ultimate biological activity.
The in vivo potency of a siRNA is thus largely predicated upon
sequence specificity and its stability against nucleases [21,22]. The
latter can be achieved through chemical stabilization of the
backbone with phosphorothioate (PS) and 29-O-methyl sugar
modifications on the sense and antisense strands [23,24], or other
chemical modifications. The conjugation of cholesterol to the 39
end of the sense strand by a pyrrolidine linker is also critical to
improve cellular uptake Addition of cholesterol prolongs circulat-
ing half live but it does not influence its silencing activity [25].
Chemically stabilization or cholesterol conjugation of siRNAs has
improved in vitro and in vivo pharmacological and pharmacoki-
netic properties.
Our group has developed a small inhibitory RNA (siRNA)
molecule against murine CD40-mRNAwhich effectively inhibits
its translation into CD40 receptor protein [26]. Therefore we here
report our experience with a chemically stabilized, cholesterol-
conjugated anti-CD40 siRNA (Chol-siRNA) in a model of LPS-
induced CD40 up-regulation to assess its potency, distribution and
durability of effect following systemic administration. We also
focus on the inhibitory effects of our Chol-siRNA CD40 in NZB/
W F1 mice with established autoimmune nephritis.
Methods
2.1. CD40-siRNA Properties
The CD40-siRNA sequence used in this study has been
previously described by our group (siRNA TNFRSF5-3). It
consists of a 21-nucleotides sense strand and antisense strand
resulting in a two nucleotides overhang at the 39 end of the
antisense strand (sense 59-GUGUGUUACGUGCAGUGACUU-
39, antisense 39-GTCACACAAUGCACGUCACUG-59).
Cholesterol siRNA (Chol-siRNA): The siRNA was chemically
stabilized with partial phosphorothioate backbone and 29-O-
methyl sugar modification on the sense and antisense strand, as
previously described [25]. And, conjugation of a cholesterol
molecule to the 39 end of the sense strand of the siRNA molecule
by means of a pyrrolidine linker was done [25]. Scrambled siRNA
(SC) was used as control. The synthesis was carried out by an
external manufacturer (Microsynth, Switzerland). To generate
siRNAs from RNA single strands, equimolar amounts of
complementary sense and antisense strands were mixed and
100% annealed.
Melting point of siRNA molecules was determined using a Jasco
V-650 spectrophotometer (Easton, MD, USA) equipped with a
Peltier unit. Oligonucleotides strands were annealed at 90uC for 3
minutes and then cooling to 20uC prior to the melting experiment.
Samples were heated at linear temperature ramp of 0.5uC/min.
Melting temperature was obtained as the maxima of the first
derivative.The melting point of the siRNA without modifications is
79uC and for the Chol-siRNA is 71uC.
2.2. Bone Marrow Preparation and Dendritic Cell Culture.
DC Activation and siRNA Transfection
Femurs and tibiae from ICR mice were left in RPMI-
1640medium (Biological Industries, Kibbutz BeitHaemek, Israel).
56106 cells were grown in 5 ml complete medium: RPMI
supplemented with Penicillin (100 U/ml), Streptomycin (100 mg/
ml), L-glutamin (2 mM, Reactiva, Almeria, Spain), 10% heat
inactivated and filtered FBS and 20 ng/ml GM-CSF (R&D
systems, Minneapolis, MN, USA) at 37uC in a humidified
atmosphere with 5% CO2. On day 3, 5 and 8 medium was
removed and fresh complete medium was added. The percentage
of immature dendritic cells was 15% 48% and 90% respectively.
At day 8 two sets of independent experiments were done; one of
them to evaluate the transfection of CD40 siRNA molecules:
dendritic cells were incubated with nude unmodified siRNA-Cy5.5
or Chol-siRNA-Cy5.5at 2 mM. Continuous cell imaging acquisi-
tion was carried out with a confocal microscopy (Leica TCS-SL
spectral) for 45 min. The other set aimed to evaluate siRNA
in vitro activity: cells were incubated with nude Chol-siRNA or
scrambled siRNA at 2 mM. At day 9 DCs were stimulated with
10 ng/ml LPS (serotype O111:B4, Sigma, Madrid, Spain).After
12 h of LPS stimuli, cells were analyzed by flow citometry using a
BD FACS CantoII Cytometer and analyzed by FACS DIVA
software (BD Biosciences, San Jose, CA, USA). To characterize
the phenotype we used the following antibodies: anti-CD11c
(clone HL3) and anti-CD11b (clone M1/70), anti CD40 (clone
HM40-3) and anti CD80 (clone 16-10A1) anti CD86 (clone GL1)
and their respective isotype controls. All antibodies were provided
by BD Biosciences, conveniently titrated, mixed together and
formulated for optimal staining performance.
2.3. Mice, Study Design and Follow Up
After proving that our siRNA effectively internalize into cells,
we tested the in vivo effects of Chol-siRNA systemic administra-
tion. For this, we used six to eight week old male ICR mice (The
Jackson Laboratory, Charles River, Spain). We analyzed CD40-
mRNA expression in kidney and liver after i.p. LPS injection (5 mg
E.Coli LPS serotype O111:B4, Sigma Aldrich, Madrid, Spain).
Animals were euthanized at 4 h and on day 1, 2. In another set of
experiments we administered on day 0 a single i.p dose of CD40
Chol-siRNA to assess the effects on kidney CD40-mRNA.
Afterwards, at predefined time points (days 0, 1, 3, 5, 7 and 9)
an i.p LPS dose was administered and animals sacrificed 4 h later.
Scrambed siRNA was used as control.
For lupus nephritis studies, five month old NZB/NZW F1 (The
Jackson Laboratory, Charles River, Spain) mice were randomized
into five groups and basal studies were done. At sixth month old,
treatment was initiated as follows: CYP (n = 9) intraperitoneal
CYP, 50 mg/kg every 10 days; CTLA4 (n = 9) intraperitoneal
CTLA4 (ORENCIA, abatacept, Bristol Myers Squibb, Spain)
50 mg thrice weekly; siCD40-1w (n = 9) intraperitoneal CD40-
siRNA 50 mg once weekly; siCD40-2w (n = 8) intraperitoneal
CD40-siRNA (Microsynth, Switzerland) 50 mg twice weekly.
Untreated (n = 15) intraperitoneal scranbled siRNA as control,
50 mg twice weekly. Mice were treated for 12 weeks. Body weight
was determined twice monthly from the beginning to the end of
follow-up. Mice were placed in metabolic cages to collect 24 h
urine specimens before the onset of treatment and monthly
thereafter. Blood was obtained from the tail vein at monthly
intervals. Kidneys were processed for histological and biochemical
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studies at the end of the study or at death. The spleen was
collected, weighted and used to extract splenocytes. Six additional
mice from the untreated group were administered I.P and I.V with
Chol-SiRNA Cy5.5 labeled to determine organ siRNA biosdis-
tribution in lupus disease.
The experiments were carried out in accordance with current
EU legislation on animal experimentation and were approved by
‘‘CEEA: Animal Experimentation Ethic Committee’’, the Institutional
Ethics UB Committee for Animal Research. Mice were housed in
a constant temperature room with a 12-hour dark/12-hour light
cycle, and were given free access to water and a standard
laboratory diet.
2.4. Proteinuria, Albuminuria and Renal Function
24 h-urinary protein was determined by pyrogallol red and
creatinine concentration was determined by Jaffe’s reaction
(Olympum Autoanalyzer AU400, Hamburg, Germany) in the
Veterinary Clinical Biochemistry Laboratory of Universitat
Autonoma de Barcelona. 24 h-urinary albumin was determined
using a commercially available ELISA KIT (Active motif,
Carlsbad, California, USA) according to the manufacturer’s
instructions. The intensity of the fluorescent signal is directly
proportional to the albumin concentration in the sample.
2.5. RNA Extraction, RT and Gene Expression Analysis:
Quantitative Real-time PCR (qPCR)
For molecular studies, the kidney was immediately snap-frozen
in liquid nitrogen and stored at 280uC. RNA was extracted from
kidney animals with PureLinkTM RNA Mini Kit (Invitrogen,
Spain) according to the manufacturer’s instructions. All samples
had an A 260/280 ratio ,1.8 purity. RNA was stored at 280uC.A
total amount of 500 ng of RNA was used to do the reverse
transcription using the High-Capacity cDNA reverse Transcrip-
tion Kit (Applied Biosystems) following the manufacturer’s
instructions. Negative controls for reverse transcription were
carried out using distilled water.
Tissue expression of immune-inflammatory mediators were
quantified by TaqMan real-time PCR (ABI PrismH 7700, Applied
Biosystems, Spain) using the comparative CT method (Applied
Biosystems, Spain). Taqman gene expression assays used were
purchased from Applied Biosystems: CD40 (Mm_00441891_m1),
IL1b (Mm_01336189_m1), NLRP3 (Mm_00840904_m1), Apelin
(Mm00443562_m1), C3 (Mm01232779_m1), CD40L
(Mm00441911_m1), CD55 (Mm00438377_m1), FOXP3
(Mm00475165_m1), IL6 (Mm99999064_m1), IL10
(Mm00439614_m1), MCP1 (Mm00441242_m1), RANTES
(Mm01302428_m1) TLR3 (Mm00628112_m1), TLR4
(Mm00445273_m1), TLR9 (Mm00446193_m1), AIM2
(Mm01295719_m1) and Eukaryotic 18S (431941E) as endogenous
control. Controls, which were composed of distilled water, were
negative for target and reference genes.
2.6. 59RACE
59 RACE PCR was performed using the 59 RACE system for
rapid amplification of cDNA ends kit (Invitrogen, Madrid, Spain)
according to the manufacturer’s instructions. Total (5 mg) mRNA
from kidney samples of siRNA treated groups was converted into
cDNA using reverse transcriptase and a specific primer
(GSP1:59GCCGACTGGGCAGGGATGACAGACG39). To de-
tect cleavage products specific cDNA is then directly amplified by
PCR using a specific primer (GSP2:59AGCCAGGGATA-
CAGGGCGTGTGC39) and an adapter primer complementary
to the RNA adaptor that targets the tail region. Amplification
products were resolved by agarose gel electrophoresis and
visualized by ethidium bromide staining.
2.7. Plasma ELISA for Anti-DNA Antibodies, CD40, and
IDO in Lupus Nephritis
Levels of anti-DNA antibodies were measured, using a
commercially available ELISA kit (Alpha Diagnostic International,
San Antonio, Texas, USA) according to the manufacturer’s
instructions. CD40 protein and indoleamine 2,3-dioxygenase
(IDO) was determined in plasma samples at the end of the study
using the commercially available ELISA kit RayBioH Mouse
CD40/TNFRSF5 (Raybiotech, Norcross, Atlanta, GA, USA) and
ELISA kit for IDO (Uscn Life Science, Wuhan, China) according
to manufacturer’s instructions.
2.8. Serum Cytokine Analysis and Immunoglobulin
Isotyping
Serum cytokines and immunoglobulin isotype were quantita-
tively measured by FACSCanto with different cytometric bead
array (CBA) kits according to manufacturer’s instructions: the
CBA mouse inflammation kit (IL6, IL10, MCP1, IFNc, TNF and
IL12p70), the CBA mouse Th1/Th2 cytokine kit (IL4, IL5, IFNc
and TNF), and mouse immunoglobulin isotyping kit, all from BD
Biosciences (San Jose, CA, USA). Data were acquired and
analyzed using BD FCAP software and CBA software (San Jose,
CA, USA).
2.9. Phenotypic Spleen Population Analysis by Flow
Citometry
Spleen was collected in PBS, the splenocytes isolated by FicollH
(GE Healthcare, Uppsala, Sweden) density gradient and cryo-
preserved at 2180uC. For quantifying the percentage of different
populations, cells were thawed, washed and recovered by standard
methods. 26105splenocytes for tube were incubated in the dark
(25 min, RT) with antibodies. Study of populations was performed
by using a BD FACS CantoII Cytometer and analyzed by FACS
DIVA software (BD Biosciences, San Jose, CA, USA). To
characterize the different cell populations we used an anti-CD19
(clone 1D3), anti-CD69 (clone H1.2F3), anti-CD25 (clone PC61),
anti-CD3 (clone145-2C11); anti-CD4 (clone RM4-5), anti-CD8
(clone 53-6.7), anti-CD11c (clone HL3), anti-CD11b (clone M1/
70),anti-IgD (clone11-26c.2a), anti-CD23 (clone B3B4), anti-
CD45R (cloneRA3-6B2), anti mPDCA-1 (clone JF05-1C2.4.1),
anti CD5 (clone 53-7.3), and anti CD1d (clone1B1). All antibodies
were provided by BD Biosciences and MiltenyBiotec, conveniently
titrated, mixed together and formulated for optimal staining
performance.
2.10. Renal Lupus Histopathology
For histopathological studies, 1–2 mm thick coronal slices of
kidney were fixed in 4% formaldehyde and embedded in paraffin.
For light microscopy 3–4 mm thick tissue sections were stained
with hematoxylin and eosin (H&E) and periodic acid-Schiff.
For determine the extent of renal damage, all renal biopsies
were analyzed by two blinded pathologists. Typical glomerular
active lesions of lupus nephritis were evaluated: mesangial
expansion, endocapillary proliferation, glomerular deposits, extra-
capillary proliferation and interstitial infiltrates, as well as tubulo-
interstitial chronic lesions: tubular atrophy and interstitial fibrosis.
Lesions were graded semi-quantitatively using a scoring system
from 0 to 3 (0 _ no changes, 1 _ mild, 2 _ moderate, 3 _ severe).
Finally, a total histological score (HS) was derived from the sum of
all the described items.
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Paraffin tissue sections were stained for CD40 (Abcam,
Cambridge, UK) and CD3 (Abcam, Cambridge, UK). Sections
were de-parafined and hydrated. The sections were blocked and
immunoperoxidase-labelled using a Vectastain ABC kit and the
avidin biotin blocking kit (Vector Laboratories, Burlingame, CA)
according to manufacturer’s protocol. Peroxidase conjugated
antibodies staining was followed by diaminobenzidine substrate
development (Sigma, Madrid, Spain). To quantify CD40 expres-
sion a semi quantitative score from 0 to 3 in the different
compartments of the kidney (glomeruli, vessels and interstitium)
was used. For quantifying CD3 expression at least 15 high-power
fields were counted and the mean value was expressed.
2.11. Renal Immunofluorescence in Biodistribution
Studies and Lupus Nephritis
Slices of kidney were fixed in 4% paraformaldehyde, embedded
in Tissue Tec OCT compound (Sakura, Netherlands) and stored
at 280u. Five-mm cryostat sections were used for confocal
microscopy to quantify the mean fluorescence intensity of
siRNA-Cy5.5 or Cy5.5 fluorochrome. At least 10 HP fields from
each organ were counted.
For analysis of IgG and C3 deposition, fluorescent staining of
cryo-sections were used. Sections were directly stained with FITC-
conjugated goat anti-mouse IgG (Sigma-Aldrich, Spain), and
FITC conjugated C3 (Nordic Immunology, Netherlands). For
analysis of C3 and IgG deposition at least 10 glomeruli were
visualized and photographed with an immunofluorescence confo-
cal microscope (Leica TCS-SL spectral). Fluorescence was
quantified with Leica software and expressed as mean fluorescence
intensity. For the localization and quantification of interstitial
plasma cells paraffin sections were stained with FITC-conjugated
goat anti-mouse IgG (Sigma-Aldrich, Spain) and rabbit anti mouse
collagen-IV (Chemicon international, Temecula, CA). Sections
were incubated with primary antibodies Col-IV and IgG in goat
serum overnight. Staining was visualized with a secondary chicken
anti goat Alexa 488 and a goat anti rabbit Alexa 546 (Invitrogen,
Madrid, Spain). For quantification of plasma cells at confocal
microscopy, a semi quantitative score of distribution from 0 to 3
was used.
2.12. Statistical Analysis
Overall survival was analyzed by the Kaplan-Meier method.
One-way analysis of variance (ANOVA) with post hoc tests was
performed to compare proteinuria, anti-dsDNA antibodies, gene
expression, and spleen population, throughout the follow up. To
compare histological data, the non-parametric Kruskal-Wallis test
was used. P value ,0.05 was considered significant. Data are
expressed as mean6SEM.
Results
3.1. DCs were Efficiently Transfected by siRNA. Chol-
siRNA Inhibited CD40 Expression in DCs
The effective transfection of siRNA into DCs was examined
using Cy5.5 labeled siRNAs. siRNA molecules were efficiently
delivered into the cell(100%)(data not shown);and as seen in
fig. 1,Chol-siRNA-Cy5.5 had a significantly higher MFI (mean
fluorescence intensity) than unmodified siRNA. To evaluate cell
viability after gene transfection, DCs were stained with propidium
iodide 12 h after LPS stimulus. Cell viability was not affected due
to the siRNA transfection.
After 45 min of DC incubation with Chol-siRNA, the molecule
was totally located in the cytoplasm of the cell (Fig. 1). This was
also confirmed by Z-scan imaging of DC. These results indicate
that Chol-siRNA is cell permeable and could be delivered
efficiently into the cells.
To investigate the effect of siRNA transfection on the expression
of CD40 gene, we used LPS to induce DC maturation and CD40
overexpression. DC maturation was confirmed by flow citometry
12 h after LPS stimulus analyzing the increase in CD40, CD80
and CD86 cell surface expression (basal vs stimulated
MFI),CD40:1.760.0 vs 12.960.2; CD80:2.860.0 vs 5.260.0;
CD86:1.260.0 vs 6.360.0). Results show that the unstimulated
DC, independently of the siRNA used, did not change CD40
expression. When cells were exposed to LPS, only DC treated with
Chol-siRNA decreased 35% the CD40 expression respect to the
control and SC group. (Fig. 1). CD80 and CD86 expression
showed a non significant reduction (results not shown). LPS
stimulus induced a clear release of TNF, MCP1 and IL6 in
supernatants. Anti CD40 siRNA administration induced a
significant reduction in all those cytokines (Fig. 1).
3.2. in vivo Study of the Inhibitory Effects of Chol-siRNA
on Renal CD40-mRNA Expression after LPS Injection
Renal and hepatic CD40-mRNA expression was nearly 20 and
35-fold higher than control, respectively, 4 hours after LPS
injection (Fig. 2). Renal CD40-mRNA expression returned
towards control values within 24 hours after LPS injection,
whereas it remained elevated for approximately 48 hours in the
liver. After a single initial Chol-siRNA administration and LPS
injection on predetermined time-points, renal and hepatic CD40-
mRNA expression was reduced by approximately 65% and 60&
respectively for 3 days compared to both controls (no siRNA and
SC group), and persisted for up to 5 days (Fig. 2). As a control,
TLR4 mRNA was activated by LPS injection. Chol-siRNA
reduced over-expression of TLR4 LPS-induced (30,1 and 12,1
folds respectively, not shown).
3.3. Animal Survival, Proteinuria and Albuminuria
Cumulative survival analyzed by Kaplan-Meier method was
100% for the CYP, CTLA4 and CD40-2w groups; 88% for the
CD40-siRNA-1w group, and 73% for the untreated group at the
end of the follow up. Proteinuria (Fig. 3a) and albuminuria (not
shown) increased progressively in untreated mice to levels of heavy
proteinuria (around 300 mg/kg) though the mortality, proteinuria
levels continued to increase. The CTLA4 and siCD40-1w groups
showed no increase in proteinuria or albuminuria until week 28,
but to a lesser extent than the untreated group. Mice treated with
CYP or siCD40-2w showed no increase in either parameter, or
even a mild reduction in proteinuria over time to levels almost
physiological.
3.4. Anti dsDNA Antibodies in Lupus Nephritis.
Immunoglobulin Isotype
IgG anti-dsDNA antibody levels increased steadily in untreated
group (Fig. 3b). As expected, CYP slowed down the production of
antibodies. Chol-siRNA produced a dose dependent reduction of
antibodies. Treatment of mice with siRNA once per week partially
reduced antibodies, similarly as CTLA4 treatment. The levels in
the CYP and siCD40-2w groups were significantly lower from
untreated at week 36 (p,0.05).
Immunoglobulin subclasses characterization showed that IgG
was the most frequent isotype in serum (Fig. 3c). Anti dsDNA
antibody, in particular of the IgG isotype are considered a
hallmark of LES and correlates with disease activity. CD40
blockade with chol-siRNA, either one or twice per week, reduced
total IgG and all IgG fractions. Levels of IgM, IgA and IgE were
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reduced in siCD40-2w group, which was significant for IgE
(Fig. 3c).
3.5. Renal Structural Effects of CD40 Chol-siRNA in Lupus
Nephritis
Renal histological analysis was performed in all surviving
animals at the end of the study (Fig. 4).Untreated mice kidneys
showed lesions consistent with proliferative lupus nephritis,
including severe glomerulonephrits, interstitial inflammation, and
widespread proteinaceous tubular casts as expected from their
severe proteinuria. Histological lesions were less severe in all
treated groups. Mean histological scores were as follow: Untreat-
ed = 861.5; CYP = 4.361.1; CTLA4 = 1.660.7; siCD40-
1w = 3.861.5; and siCD40-2w = 1.660.6. (p = 0.011) being
Figure 1. Representative flow cytometry analysis of DC culture. A) DC culture development. Lymphocytes (CD3+) and death cells (IP positive)
were discarded. DCs were backgated using a FSC-A/SSC-A dot plot. Subsequently, CD11c and CD11b expression were assessed in DC population
using CD11c APC/CD11bPE dot plot. D0, D3, D5 and D8=day 0, 3, 5 and 8 respectively B) CD40 expression of DC with and without LPS stimuli and
transfected with Chol-siRNA or SC siRNA were analyzed by flow cytometry (MFI). *p,0.05 vs control and scrambled. C) Representative histograms for
each group of treatment. D) Representative histograms of siRNA internalization analyzed by flow citometry (MFI). E) DC cytokine secretion after LPS
stimulus and Chol-siRNA effect. F) Chol-siRNA Cy5.5 internalization in DCs is shown at time 0 and after 45 min of incubation (upper left and right
photomicrograph x630, respectively). Middle and bottom photomicrographs: Z-scan image of live DC cells where we can observe siRNA cytoplasm
localization and confocal projections of the cell to the xz and zy planes (sideviews). Data are expressed as mean6 SEM of four separate experiments.
doi:10.1371/journal.pone.0065068.g001
Figure 2. In vivo CD40 expression after LPS stimulus and Chol-siRNA. A) ) Kinetic of CD40 expression in liver and kidney after LPS injection, a
peak of CD40 expression at 4 h was seen. There were no differences using scrambled siRNA. B) Pharmacodynamic evaluation of Chol-siRNA. Mice
receiving a single dose of Chol-siRNA at day 0 and a single injection of LPS at pre determined time points showed reduction on liver and kidney CD40
gene expression. Data are expressed as mean6 SEM of four separate experiments.
doi:10.1371/journal.pone.0065068.g002
Silencing CD40 in Lupus Nephritis
PLOS ONE | www.plosone.org 5 June 2013 | Volume 8 | Issue 6 | e65068
siCD40-2w and CTLA4 groups statistically significant respect to
control group. With regards to individual histological lesions, the
siCD40-2w group was remarkable for the absence of extracapillary
proliferation, interstitial infiltrates, tubular atrophy, or interstitial
fibrosis. This effect was clearly better than mice receiving siRNA
once a week.
Figure 3. Proteinuria, anti dsDNA antibodies and Immunoglobulin isotype. A) 24 h-Proteinuria increased progressively in non treated mice
to levels of heavy proteinuria. Treatment with CYP or siRNA anti CD40 twice per week induced a progressive reduction of proteinuria to levels almost
physiological. B) Anti dsDNA antibodies increased progressively in non treated mice; siRNA anti CD40 twice per week reduced this production more
effectively than CTLA4 or siCD40-1w group. C) Circulating immunoglobulin subclasses characterization. CD40 blockade with Chol-siRNA reduced total
IgG and all IgG fractions. Data are expressed as mean6SEM of four separate experiments, p,0.05 a vs untreated.
doi:10.1371/journal.pone.0065068.g003
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3.6 in vivo Determination of CD40 Chol-siRNA Renal
Release and Effective CD40 mRNA Cleavage in Lupus
Nephritis
Additional lupus mice that received Chol-siRNA Cy5.5 labeled
one hour before the sacrifice, showed an intense fluorescence in
tubular cells (Fig. 5). Thus in the kidney the fluorescence intensity
doubled the basal value.
To prove that the in vivo activity was due to siRNA-directed
cleavage, we characterized specific CD40 mRNA cleavage
products using a 59-RACE technique. Total RNA from mice
was isolated from renal tissue, and then PCR and agarose gel were
used to reveal fragments of the predicted length in those animals
with lupus nephritis receiving chol-siRNA (Fig. 5). This demon-
strates that cleavage occurred at the predicted position for the
siRNA duplex, ten nucleotides downstream of the 59 end of the
siRNA antisense strand. To further assess the cleavage of siRNA in
immune cells we performed the 59-RACE technique on dendritic
cells stimulated by LPS and treated with siRNA anti CD40 and a
correct cleavage was seen (Fig. 5).
3.7. CD40 Silencing Reduces IgG and C3 Glomerular
Deposits
IgG glomerularimmunostaining was reduced by all treatments
as compared to untreated untreated animals (Fig. 6a).Both
CTLA4 and siCD40-2w produced similar reductions in IgG
immune-fluorescence scores, which were lower than in the CYP
group. C3 deposits were also reduced in all treatment groups,
although in this case scores in the CYP and siCD40-2w were lower
than in the CTLA4 and siCD40-1w group. (Fig. 6a).
3.8. Renal Gene Expression and CD40 Protein Analysis
After Silencing in Lupus Nephritis
The analysis of kidney gene expression (Table 1) showed a
statistically significant reduction in CD40 expression with CYP
and siCD40-2was compared to the untreated and CTLA4 groups.
All treatment groups produced a significant reduction in CD40L
compared to untreated (except siCD40-1w).
C3 gene expression, as a manifestation of local complement
synthesis, was significantly reduced by in all treatment groups
except siCD40-1w and mirrored the results of glomerular C3
deposition analysis. There was no evidence of activation of TLR3,
TLR4 and TLR9 expression in any treatment group as compared
to untreated values. Pro-inflammatory cytokine gene expression,
such as IL6, was again significantly reduced in all treatment
groups except siCD40-1w. Gene expression of the inflammasome
components AIM2, NALP3 and IL1b was significantly reduced in
all treatment groups.AIM2 is an inflammasome component known
to be a sensor for dsDNA and an activator of caspase 1.Gene
Figure 4. Renal histopathology. A) Costimulatory blockade reduced the elementary histological lesions of lupus nephritis. B) Representative
photomicrograph (x200) of renal histology for each group. Data are expressed as mean6SEM *p,0.05 vs untreated, p,0.01 vs untreated.
doi:10.1371/journal.pone.0065068.g004
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expression corresponding to the immune-modulatory mediators
FOXP3 and IL10was significantly reduced in all treatment groups,
particularly CYP. However siCD40-2w did not reduce its gene
expression as strongly as CYP. siCD40-2w was the only treatment
which up-regulated the expression of apelin, as previously shown
by our group [27].
The presence of CD40 protein in various renal tissue
compartments was quantified by immune-staining (Fig. 7b).
Significant reductions were observed in the interstitial, glomerular,
and vascular compartments in all treatment groups as compared to
untreated, where high amounts were present in all three
compartments. siCD40-2w especially reduced CD40 protein in
interstitial cells and vessels.
3.9. Systemic Circulating Cytokines in Lupus Nephritis
Lupus nephritis induced an increase in circulating CD40
protein (319698 versus76612pg/ml in healthy mice).Circulating
levels ofCD40 protein (Fig. 7a) were significantly reduced
(P = 0.019) in all treatment groups as compared to the high levels
observed in the untreated group.
Also, serum levels of pathogenic pro-inflammatory cytokines,
such as IL12, TNF, IFNc, MCP1 and IL6, were increased
compared to healthy animals (data not shown). A clear reduction
in all of them was seen by siRNA anti CD40 twice per week
treatment (Fig. 7a).
Circulating levels of the adaptive immune-modulatory IDO
protein (Fig. 7a) were also significantly reduced (P = 0.035) in all
treatment groups except siCD40-2w where the difference from
untreated did not reach statistical significance.
3.10. Analysis of Splenic Lymphoid Cell Subsets in Lupus
Nephritis
Spleen weight was higher than normal in untreated group
animals and was significantly reduced in the CYP and siCD40-2w
treatment groups (data not shown).
Phenotypic characterization of splenic lymphocytes by flow
cytometry (Table 2) showed a significant reduction in CD3+ cells
in all treatment groups, whereas activated CD3 subpopulations, as
well as the CD4+/CD8+ ratio, where reduced by CYP and
siCD40-2w (data not shown). Spleen Treg cells
(CD3+CD4+CD25+) showed a non significant reduction in CYP
group, with no differences between the other groups (Table 2).
Plasmacytoid DCs (pDC) (CD11c+CD11b-B220) were signifi-
cantly augmented in CYP group. Conventional DC (cDC) are
usually divided into CD8+ or CD8-; in our study cDC CD8+ were
significantly reduced in those groups with costimulation blockade.
There were no changes in cDC CD8- between different groups
(Table 2).
With regards to CD19+ B-cells, only CYP caused areduction
whereas early B-cell activation markers(CD19+CD25+CD69+ &
CD19+CD69+) showed a significant reduction only in both
CD40-siRNA groups. This suggests that, while CYP can reduce
overall B-cell populations, it does not affect their activation process
whereas costimulation blockade reduces early B cell activation but
not overall B cell population.
Breg cells (CD19+CD5high CD1dhigh) were significantly aug-
mented in CYP and siCD40-2w groups. Interestingly, there was
an inverse correlation between the percentage of spleen Breg cells
and the levels of circulating anti dsDNA antibodies (p = 0.018,
r = 0.5) Innate B1 cells (CD19+B220lo CD23-IgDlo) showed a
significant increase in groups treated with siRNA anti CD40,
either once or twice per week. There was no differences respect to
the percentage of conventional B2 cells (CD19+B220highCD23-
highIgDhigh) between different groups. Plasma cells (CD19+B220-
CD9+CD23-IgD-) were significantly increased in CYP group, but
no in siCD40 treated groups (data not shown).
3.11. Characterization of Cell Infiltrates and Localization
of IgG-secreting Plasma Cells in the Kidney
Infiltrating CD3+ cells in the tubule-interstitium space were
significantly reduced in all treatment groups except siCD40-1w
Figure 5. siRNA-mediated cleavage of CD40 mRNA in vivo. Confocal fluorescence and brightfield images of siRNA internalization
in DC. A) Schematic representation of the CD40 mRNA illustrating siRNA cleavage sites and RACE strategy to detect cleavage product. Agarose gel of
RACE–PCR amplification showing specific cleavage products in different lupus nephritis samples (S1 and S2), and in vitro DC culture (S3 and S4). B)
Quantification of renal internalization of Chol-siRNA administered iv/ip in lupus mice. C) Representative kidney photomicrographs (x400) of 1- Basal
auto fluorescence, 2- iv administration, 3- ip administration. Data are expressed as mean6SEM of four separate experiments.*p,0.05 vs basal.
doi:10.1371/journal.pone.0065068.g005
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(Fig. 8a); more particularly in the CYP and siCD40-2w groups
where scores were significantly lower than in the CTLA4 and
siCD40-1w groups.
The presence of anti-dsDNA antibody secreting plasma cells in
the kidneys of patients with lupus nephritis has been previously
reported [28]. Thus, we performed a double immune-staining of
renal tissue with anti-collagen-IV (red in Fig. 8c) and anti-IgG
Figure 6. Immunohistochemical analysis for renal IgG and C3. A) Deposits of renal IgG and C3 were quantified with confocal microscopy
(MFI). All treatments reduced glomerular deposits. B) Representative photomicrographs of C3 deposits (x630) for each group. Data are expressed as
mean6SEM. *p,0.05 vs untreated, ? p,0.01 vs untreated.
doi:10.1371/journal.pone.0065068.g006
Table 1. Kidney gene expression.
Fold/18S CD40 CD40L C3 CD55 TLR3 TLR4 TLR9 FOXP3
UNTREATED 1,3760,1 5,361,4 47,3614,1 1,0260,08 1,760,1 2,960,4b 8,261,1b 34,866,4
CYP 0,5560,1 a,c 1,760,3a 10,560,9a 0,7460,04a 1,460,1 1,460,1 1,760,1 7,261,3a
CTLA4 1,1760,2 2,860,5a 18,864,8a 0,7960,08a 1,460,1 1,960,2a 5,161,1b 20,365,6a, b
siCD40-1w 160,3 3,860,3b 38,8614,6b 0,8160,04a 1,660,1 2,560,3b 7,160,9b 24,662,6b
siCD40-2w 0,660,2a,c 2,260,4a 16,363a 0,6260,07a 1,760,1 2,560,3b 7,461,6b 20,963,8a, b
P 0,0251 0,004 0,03 0,01 0,17 0,02 0,0009 0,0034
Fold/18S IL10 IL6 MCP1 RANTES AIM2 NLRP3 IL1b APELIN
UNTREATED 90,9620,5 9,363,6 9,361,9b 9,361,3b 11,362,2 2,760,4 11,962,1 6,260,9d
CYP 6,162,1a 0,760,15a 260,2 1,960,3 1,460,2a 0,660,2 1,860,3 6,360,4d
CTLA4 34,869,3a 3,360,9a 5,961,7 7,462,5 4,661,1a 2,0860,3 6,561,7 6,260,4d
siCD40-1w 44,169,6a, b 6,162,5b 7,361,9b 9,663b 7,961,9a,b 1,560,4 8,861,6 5,560,4d
siCD40-2w 35,45612,9a 1,860,3a 6,561,2b 7,861,7 4,961,0a 1,360,7 1,961,0 12,161,1
P 0,0005 0,024 0,039 0,09 0,0046 0,019 0,0007 0,0001
Our Chol-siRNA specifically knocked-down CD40 expression. Complement activation, inflammasome and innate immunity gene expression was reduced. a vs
control,n = 9 per group. One-way analysis of variance (ANOVA) with post hoc tests was performed to compare groups. a vs control, b vs CYP, c vs CTLA4, d vs siCD40-2w.
p,0,05.
doi:10.1371/journal.pone.0065068.t001
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(green in Fig. 8c). In untreated animals, plasma cells were mainly
observed in the tubule-interstitium of the renal cortex where
dendritic cells, macrophages, and other inflammatory cells are
commonly found [28].A significant reduction in IgG immune-
fluorescence was observed in all treatment groups, particularly in
the CTLA4 and both CD40-siRNA groups (Fig. 8b).
Discussion
Our data from a well-recognized experimental murine model of
autoimmune nephritis shows that interfering with the expression of
the co-stimulatory molecule CD40 with a selective siRNA results
in improved animal survival and reduces the progression of the
disease process, as illustrated by the absence of progressive
proteinuria. These effects in mice were accompanied by signifi-
cantly reduced circulating anti-dsDNA antibody titers, a hallmark
of the disease, and renal histo-pathological lesions to a degree
which was surprisingly comparable to those obtained with
cyclophosphamide. Our data also show highly concordant
reductions in intra-renal cellular (T-cells, plasma cells), and non-
cellular (IgG and C3 deposits) inflammatory components, as well
as circulating CD40, IFN, TNF, IL6, MCP1, IL12 factors with
obvious pathogenesis implications.
First of all we chose LPS-induced CD40-mRNA up-regulation
as a particularly challenging model where to test the potency and
pharmacokinetics/dynamics of our Chol-siRNA. There, our data
show that LPS induces large increases in CD40-mRNA expression
in both liver and kidney tissue which can be significantly reduced
Figure 7. Systemic circulating inflammatory cytokines and local CD40 immunostaining. A) Lupus nephritis promoted over-expression of
CD40 protein in serum, this immune modulatory protein was reduced in all therapies. Lupus nephritis also induced the increase in other inflammatory
cytokines, treatment with siRNA anti CD40 reduced some of them. B) Immune localization and quantification of CD40 protein in different kidney
compartments, Chol-siRNA reduced CD40 protein, especially in interstitial cells and vessels. Data are expressed as mean6SEM. a p,0.05 vs untreated;
b vs CTLA4, c vs CYP and d vs siCD40-2w.
doi:10.1371/journal.pone.0065068.g007
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by a single dose of Chol-siRNA. Its suppressive effect is
remarkably long-lasting in both liver and kidney, particularly so
in the latter where it remains unabated for the first 3 days.
Interestingly, the biodistribution fluorescence studies showed an
excellent internalization into those parenchymas. There is no
discernible difference with the I.P. and I.V route with regards to its
persistence over time.
The CD40-CD154 co-stimulatory dyad plays a central role in
the development of immune-inflammatory disease processes
[6,29]. Disruption of CD40 signaling offers the potential of being
therapeutically useful in autoimmune inflammatory disorders or in
the prevention of allograft rejection [26]. Blocking monoclonal
antibodies against CD40L have reached the clinical testing stage
but their development has been halted due to athero-thrombotic
complications in study subjects [17,18]. Cyclophosphamide has
been in use for decades to treat SLE and LN, but its short and long
term toxicity and relatively low effectiveness in preventing disease
relapse [10] has made its use progressively less prevalent, as more
than 50% of patients with lupus nephritis relapse within two years
after cessation of therapy. Besides cyclophosphamide, we included
in our experimental design CTLA4, which was only as powerful as
a single weekly dose of CD40-siRNA in halting the progression of
proteinuria, clearly a sub-therapeutic dose when compared to the
effects of the bi-weekly CD40-siRNA dosing regimen.
SLE is characterized by excessive activation of both B and T
lymphocytes, as well as abnormalities in B-cell activation,
signaling, and migration [30,31]. In this study we found a
decrease in the frequency of spleen B cells in mice treated with
CYP compared with untreated mice. Costimulatory blockade with
our siRNA anti CD40 did not modify the percentage of B cells, but
in contrast, it prevented early activation of spleen B and T cells. It
could be speculated that reduction of dsDNA antibodies in siRNA
treated mice is probably due to the modulation of B-cell rather
than an antiproliferative effect. In concordance, Breg and B1 cells
were clearly increased in animals receiving CD40 siRNA twice per
week. The clear-cut inverse correlation between Breg and anti
dsDNA antibodies titters also argues in favour of this. Breg cells
have a modulatory function by suppressing IFNc and TNF from T
cell, and releasing several regulatory cytokines. Similar to Breg, B1
cells exert immunosuppressive effect [32]. We did not find
differences in Treg population in our study thus it may be argued
that in this model the regulatory arm should be more related to
Bregs than Tregs.
Any of studied treatments induced differences in overall
CD11c+ population, but siRNA anti CD40 treatment twice per
week was able to significantly reduce CD40 expression in those
cells. The cDC CD8+ are thought to be important maintaining
self-tolerance and, in vivo, they secrete high amounts of IL12 and
IFNc [31], inducing a Th1 response. On the other part, cDC
CD8- mainly induce Th2 response and secrete low levels of IL12.
Of note, in our study no differences between cDC CD8- were
found but a significant reduction of cDC CD8+ in both siRNA
groups was seen.
Effective CD40 gene silencing appears also to produce systemic
effects as is the reduction of immune system response, as illustrated
by the decrease in circulating CD40, IL12, TNF, IFNc, MCP1,
IL6 proteins. CD40-siRNA did not increase the expression of the
immune-modulatory mediator neither local nor circulating IL10,
which was locally reduced by cyclophosphamide. The role of IL10
in LES is controversial, it has been considered as an anti-
inflammatory mediator, but some studies demonstrate that the
administration of IL10 accelerates the onset of renal disease, high
serum levels of IL10 are found in patients with SLE and correlates
with the disease activity [33–35].
Recently, antibody secreting cells were found within the
inflamed kidneys in experimental as well as human SLE
[28,36,37]. In our study we confirmed the presence of plasma
cell within the renal interstitium of lupus non treated mice; their
presence was diminished in siRNA CD40 treated groups. These
data may suggest that our siRNA exerts an intense local effect on
plasma cell nidation, added to the systemic benefit on B-cell
activation.
The complement system plays a dual role in the pathogenesis of
LN [38,39]. It is known that kidney contributes to the circulating
pool of C3, approximately for 9% of the total circulating protein
[40]. In our study siRNA anti CD40 treated mice showed an
important down regulation of glomerular C3 deposits. In addition
the reduction of C3 gene expression in the kidney in siRNA twice
per week informs that CD40 gene silencing also reduces the local
synthesis of complement. Apart from complement modulation,
Table 2. Immunomodulation of spleen cell population (%).
%GROUP CD3+ Treg CD11c+ pDC cDC CD8+ cDC CD8-
UNTREATED 42,662,1 9,1661 10,161,1 15,461,9b 12,361,3 38,862,6
CYP 34,261,6a 5,3261,2 11,860,7 26,862,5 12,360,8 44,161,1
CTLA4 31,161,2a 9,4861,9 10,660,6 15,862,4b 7,160,6a 37,463,4
siCD40-1w 32,161,9a 10,4860,8 11,861,7 19,460,9b 8,861,2a 36,860,8
siCD40-2w 31,161,5a 8,8861,9 9,460,6 13,861,8b 8,460,4a 40,862
P 0,0011 NS NS 0,002 0,006 NS
% CD19+ CD19+CD69+ CD19+CD25+CD69+ Bregs B1 B2
UNTREATED 39,563,7 10,662,5 3,260,7 6,660,9 11,260,9 60,961,7
CYP 31,762,1 7,261,1 2,760,5 12,461,3a 15,462,1 48,663,0
CTLA4 43,260,8b 7,260,4 2,360,2 5,7861,9 11,861,6 53,367,2
siCD40-1w 37,864,6 6,261,1 1,660,3a 5,961,8 18,263,4a 48,867,3
siCD40-2w 39,762,1 4,161,1a 1,160,3a,b 10,361,8a 18,963a 51,964,3
P NS 0,045 0,05 0,022 0,07 NS
The percentage of B cell was diminished with CYP treatment, CD40 silencing reduced early B cell activation but not overall B cell population. n = 9 per group. One-way
analysis of variance (ANOVA) with post hoc tests was performed to compare groups. a vs control, b vs CYP, c vs CTLA4, p,0,05.
doi:10.1371/journal.pone.0065068.t002
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infiltrating T-cells were reduced as an effect of CD40 silencing
thus suggesting a modulation of subsequent local inflammatory
response.
Gene expression analysis corroborated the reduced CD40 and
inflammatory cytokines in renal tissue without evidence of toll-like
receptor activation. This is a pathway for innate immune system
activation of potential concern with the use of siRNAs, particularly
with regards to TLR3[41–43]. In our study, the expression of
TLR9 was expectedly increased in non treated animals, and was
dramatically reduced by cyclophosphamide but not CTLA4 or
CD40-siRNA, suggesting that, in contrast to cyclophosphamide,
co-stimulatory blockade does not impair innate immunity through
this pathway.
In conclusion, our data strongly supports the potential
therapeutic effects of selective CD40 blockade as a powerful form
of immune deactivation in the inflamed kidney of animals with
spontaneous autoimmune nephritis akin to human lupus nephritis,
particularly when treatment is instituted during the early phases of
the disease. It remains to be seen whether disease remission could
be achieved through CD40 RNA-interference initiated during the
established phase of the disease, since patients with lupus nephritis
often present with established proteinuria and severe renal
inflammation.
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